Karin Jooss
Chief Tech/Sci/R&D Officer at GRITSTONE BIO, INC.
Net worth: 340 443 $ as of 2024-04-29
Karin Jooss active positions
| Companies | Position | Start | End |
|---|---|---|---|
| GRITSTONE BIO, INC. | Chief Tech/Sci/R&D Officer | 2016-04-12 | - |
| FATE THERAPEUTICS, INC. | Director/Board Member | 2019-03-13 | - |
| Independent Dir/Board Member | 2019-03-13 | - |
Career history of Karin Jooss
Former positions of Karin Jooss
| Companies | Position | Start | End |
|---|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | 2009-04-30 | 2016-03-31 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Chief Tech/Sci/R&D Officer | 2001-06-30 | 2009-03-31 |
Training of Karin Jooss
| Philipps University of Marburg | Doctorate Degree |
Statistics
International
| United States | 5 |
| Germany | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| GRITSTONE BIO, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
- Stock Market
- Insiders
- Karin Jooss
- Experience
